Pieper Steven 4

4 · Xeris Biopharma Holdings, Inc. · Filed Feb 2, 2026

AI-generated summary of this filing

Updated Feb 2, 2026

Xeris (XERS) CFO Steven Pieper Sells Shares to Cover Taxes

What Happened

Steven Pieper, Chief Financial Officer of Xeris Biopharma, received equity awards and had shares withheld to satisfy tax-withholding obligations. On Jan 30, 2026 he was granted 154,986 restricted stock units (RSUs) and 207,207 derivative stock options (both $0 exercise price reported as grants). On Jan 31, 2026 a total of 205,534 shares were withheld/disposed at $7.36 per share to cover taxes, generating proceeds of $1,512,730 (111,765 @ $7.36 = $822,590; 66,450 @ $7.36 = $489,072; 27,319 @ $7.36 = $201,068).

Key Details

Transaction dates: Jan 30, 2026 (grants); Jan 31, 2026 (share withholding/disposition).
Prices/values: Withheld shares disposed at $7.36 each; total withholding value = $1,512,730. Grants reported at $0.00 (standard for awards).
Shares owned after transaction: Not specified in the provided filing.
Footnotes:
- RSUs (F1): Each RSU represents a right to one share; RSUs vest in equal annual installments over three years, subject to continued employment.
- Withholding (F2): The 205,534 shares were withheld by the issuer to satisfy income tax and withholding obligations in connection with the net settlement of RSUs vested as of Jan 31, 2026.
- Options (F3): Stock options were granted and vest in equal annual installments over three years, subject to continued service.
Filing: Report filed Feb 2, 2026, reporting Jan 30–31, 2026 transactions.

Context

The disposals were tax-withholding transactions (code F), a routine administrative action when RSUs vest and do not necessarily signal a voluntary sale or change in insider sentiment. The grants (RSUs and options) are subject to multi-year vesting schedules; the options were not exercised and the RSUs were net-settled (shares withheld to cover taxes).

Form 4

Period: 2026-01-30

See Remarks

Transactions

Award
Common Stock
[F1]
2026-01-30+154,986→ 1,572,547 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−111,765$822,590→ 1,460,782 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−66,450$489,072→ 1,394,332 total
Tax Payment
Common Stock
[F2]
2026-01-31$7.36/sh−27,319$201,068→ 1,367,013 total
Award
Stock Option (Right to Buy)
[F3]
2026-01-30+207,207→ 207,207 total
Exercise: $7.36Exp: 2036-01-30→ Common Stock (207,207 underlying)

Footnotes (3)

[F1]These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
[F2]Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
[F3]These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Signature

/s/ Beth Hecht, Attorney-in-Fact|2026-02-02

1 file